

REVIEW

Open Access

VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD/UBR5 E3 ubiquitin ligases

Tadashi Nakagawa^{1*}, Koushik Mondal² and Patrick C Swanson^{2*}

Abstract

The terminal step in the ubiquitin modification system relies on an E3 ubiquitin ligase to facilitate transfer of ubiquitin to a protein substrate. The substrate recognition and ubiquitin transfer activities of the E3 ligase may be mediated by a single polypeptide or may rely on separate subunits. The latter organization is particularly prevalent among members of largest class of E3 ligases, the RING family, although examples of this type of arrangement have also been reported among members of the smaller HECT family of E3 ligases. This review describes recent discoveries that reveal the surprising and distinctive ability of VprBP (DCAF1) to serve as a substrate recognition subunit for a member of both major classes of E3 ligase, the RING-type CRL4 ligase and the HECT-type EDD/UBR5 ligase. The cellular processes normally regulated by VprBP-associated E3 ligases, and their targeting and subversion by viral accessory proteins are also discussed. Taken together, these studies provide important insights and raise interesting new questions regarding the mechanisms that regulate or subvert VprBP function in the context of both the CRL4 and EDD/UBR5 E3 ligases.

Keywords: VprBP, DCAF1, DDB1, Cul4, CRL4, EDD, UBR5, Dyrk2, Merlin, Katanin, UNG2, LGL2, Mcm10, Histone H3, ROR α , Methyl degren, p53, TERT, telomerase, RAG1, V(D)J recombination, HIV, Vpr, Vpx, UL35, Ubiquitin, E3 ubiquitin ligase, RING, HECT, WD40 repeat

Introduction

Virtually all cellular processes are subjected to some level of regulation by the ubiquitin modification system which mediates the attachment of ubiquitin or ubiquitin-like molecules to proteins in the involved pathways (for review, see [1]). It is also now appreciated that this system can be subverted by pathogens to disable host responses and alter the cellular environment to benefit the microorganism (for reviews, see [2-4]). Ubiquitin is a 76 amino acid protein that is covalently attached to a target protein through a series of enzymatic steps in which free ubiquitin is initially coupled to an activating enzyme

(E1) in an ATP-dependent reaction, and then transferred to the catalytic cysteine of a conjugating enzyme (E2). In the last step, the ubiquitin-linked E2 associates with an ubiquitin ligase (E3), which catalyzes the transfer of ubiquitin to an ϵ -amino group of a lysine residue in the targeted protein. Additional ubiquitin molecules may be appended to lysine residues in ubiquitin to form polyubiquitin chains. The number of attached ubiquitin molecules and the specific lysine residue(s) used to link them together dictate whether the outcome of ubiquitination mainly serves to alter the function of the target protein, or triggers its degradation through the proteasome pathway.

There are two major classes of E3 ubiquitin ligases (termed E3 ligase henceforth) that differ in how they mediate ubiquitin transfer (for reviews, see [1,5]). Those that contain a RING (*really interesting new gene*) domain, or the related U-box domain, facilitate the direct transfer of ubiquitin from the ubiquitin-E2 conjugate to

* Correspondence: tnakagaw@med.tohoku.ac.jp; pswanson@creighton.edu
¹Department of Cell Proliferation, United Center for Advanced Research and Translational Medicine, Graduate School of Medicine, Tohoku University, Sendai 900-8575, Japan
²Department of Medical Microbiology and Immunology, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA

the target protein without forming a covalent intermediate. By contrast, those with a HECT (*homologous to E6-AP carboxy terminus*) domain first undergo a trans-thioesterification reaction which transfers ubiquitin from the E2 enzyme to an active site cysteine residue in the HECT domain before the ubiquitin is ultimately coupled to the target protein. Most eukaryotic organisms have only a single E1 activating enzyme, but express tens of E2 conjugating enzymes and several hundred or more E3 ligases. Substrate specificity is largely determined by the E3 ligase; however, the substrate binding and catalytic activity of a given E3 ligase may or may not be found within the same molecule. The cullin RING ligases (CRLs) are a large group of E3 ligases with separable substrate binding and catalytic activities (for review, see [6,7]). These E3 ligases have a modular organization in which one of the cullin family members of scaffold proteins binds both a small RING-containing catalytic subunit (Roc1 [*regulator of cullins 1*] or Roc2; also called Rbx1 [*RING box protein*] or Rbx2), and a cullin-specific adaptor protein. In most cases, the adaptor protein, in turn, binds a substrate recognition subunit that recruits and positions the substrate in proximity to the catalytic subunit for ubiquitination. The CRL is defined by the cullin scaffold protein, of which there are seven members in humans and mice (i.e. CRL1 contains Cul1). Because the CRL adaptor protein is generally cullin-specific, it is often not included in the designation, but the substrate recognition subunit is included after the CRL in superscript. For example, Damaged DNA binding protein 1 (DDB1) is the adaptor protein for the CRL4 E3 ligase. The DDB1-Cul4 associating factors (DCAFs) that comprise the substrate recognition subunits for the CRL4 E3 ligase are indicated as CRL4^{DCAF}. This convention will be followed here.

The HECT-domain E3 ligases are characterized by the presence of a C-terminal HECT domain (for review, see [8]). This family has been further divided into three broad subgroups based on the presence or absence of additional WW or RCC1 (*regulator of chromatin condensation 1*)-like domains (RLDs) in the amino-terminal region of the protein. These include the Nedd4/Nedd4-like subgroup which contains WW domains (identified by a signature pair of tryptophan residues), the HERC (*HECT and RCC1-like domain*) subgroup which contain RLDs, and a subgroup which harbors neither WW domains nor RLDs (non-WW/non-RLD). In contrast to the CRL family of E3 ligases, HECT-domain E3 ligases more commonly function as a single subunit E3 ligase, mediating both substrate recognition and ubiquitination. However, for some HECT E3 ligases, such as Nedd4, adaptor proteins may be engaged to mediate substrate recruitment or influence the subcellular distribution of the E3 ligase to direct ubiquitination of localized


substrates [9]. The degree of flexibility of adaptor proteins and substrate recognition subunits to service multiple E3 ligases is important for understanding how the substrates they recruit are regulated in a variety of spatial and temporal contexts.

Here we review and discuss the discovery and characterization of Viral protein R binding protein (VprBP, also called DCAF1), and its emerging role as a dual-purpose substrate recognition subunit for two distinct E3 ligases: the RING-family member CRL4 and the “non-WW/non-RLD” HECT-family member EDD/UBR5 (*E3 ligase identified by differential display/ubiquitin protein ligase E3 component n-recognin 5*) (Figure 1). Regulatory roles of the CRL4 and EDD/UBR5 E3 ligases for which there is no known involvement of VprBP as a substrate recognition molecule will not be discussed in depth here.

VprBP: discovery and early association with the CRL4 E3 ligase

In addition to the main Gag, Pol, and Env open reading frames (ORFs), primate lentiviruses, including human immunodeficiency virus 1 (HIV-1), have additional ORFs encoding a variety of other regulatory and accessory factors, one of which is named Viral protein R (Vpr). By the early 1990s, Vpr was known to play a key role in promoting viral replication but its function remained enigmatic. Hypothesizing that Vpr targets a host protein to mediate its function, Zhao *et al.* used purified, bacterially expressed Vpr as bait to isolate Vpr-interacting proteins from HeLa cell nuclear extracts by co-immunoprecipitation (co-IP) [10]. This screen yielded a protein initially called Vpr interacting protein (RIP), which was renamed VprBP in their subsequent study in which the authors cloned the VprBP cDNA, mapped the Vpr-interacting region to residues 636–1507 of VprBP [11], and showed that VprBP binding to Vpr promotes cytoplasmic retention of Vpr. However, the normal function of VprBP and the significance of VprBP-mediated cytoplasmic sequestration of Vpr for HIV replication remained unclear.

A major breakthrough in understanding the normal role of VprBP came from proteomic screens designed to identify DDB1-associated substrate recognition subunits for the CRL4 E3 ligase [12–15]. VprBP was identified in three of these studies [12–14] (called DCAF1 by Jin *et al.* [12] and Angers *et al.* [13]). Most identified DDB1-interacting proteins share a common structural motif called a WD40 domain (for reviews, see [16,17]). The WD40 domain contains multiple WD40 repeats (ranging from 4–16), each spanning 40–60 residues and bearing a signature Trp-Asp (WD) dipeptide at its C-terminus, although the Trp-Asp dipeptide is sometimes substituted by Tyr-Asp, Ile-Asp, or Trp-Cys in the DCAFs. In most DCAFs, including VprBP, the Trp-Asp dipeptide is also



followed by an X-Arg (or occasionally X-Lys) dipeptide. This sequence, designated a WDXR motif, is often evolutionarily conserved between orthologous DCAFs, and mutational analysis suggests that the basic residue within the WDXR motif is required for stable association of DCAF proteins to DDB1. Each WD40 repeat is composed of four anti-parallel beta-strands that form a beta-propeller; consecutive beta-propellers are connected by a peptide linker.

DDB1 itself contains three WD40 beta-propeller domains (BPA, BPB, and BPC) and a C-terminal helical domain [13]. Crystal structures of DDB1 bound to different substrate recognition subunits, including DDB2 [18-20] and Cockayne Syndrome A (CSA) [18], reveal a common mode of binding in which the WD40 beta-propeller domain in DDB2 and CSA stabilizes association with DDB1 by mediating hydrophobic contacts with the BPA domain of DDB1 and by anchoring an amino-terminal helix-loop-helix motif that is inserted into a cavity at the interface between the BPA and BPC domains of DDB1. Notably, some viral proteins, such as hepatitis B virus X protein, are able to subvert the CRL4 E3 ligase by using an alpha-helical motif to bind DDB1 at the BPA-BPC interface in a manner analogous to cellular CRL4 substrate receptors [21]. Whether VprBP shows a mode of DDB1 binding similar to DDB2 and CSA remains unclear, as no readily identifiable counterpart to the helix-loop-helix motif in DDB2 and CSA has been detected in VprBP [18,21]. VprBP preferentially binds DDB1 associated with a form of Cul4 that has

been post-translationally modified, most likely by NEDD8 although this was not experimentally confirmed [22]. In the next sections, we will review current knowledge regarding VprBP domain structure and organization, discuss the different cellular processes regulated by VprBP through its association with the CLR4 E3 ligase and its more recently uncovered affiliation with the EDD/UBR5 E3 ligase, and highlight recent insights on the effects of VprBP targeting by viral accessory proteins.

VprBP: domain organization and structural features of VprBP-DDB1 and CRL4^{VprBP} complexes

The human and murine VprBP genes express two or three predicted spliced transcript variants encoding distinct isoforms. The most similar and best characterized human and murine isoforms of VprBP are 1507 and 1506 amino acids, respectively, and share 98% identity. A predicted Armadillo-type fold domain encompasses most of the amino-terminal half of the protein (residues 80–796) (see Figure 2). This region consists of tandemly arrayed Armadillo repeat motifs, each about 40 amino acids in length, which are predicted to form layers of alpha helices that assemble into a right-handed super-helix [23,24]. These structures present a large solvent-accessible surface area well-suited for mediating contact with interacting proteins. Within this region lies a small chromo-like domain (residues 562–593), similar to those found in chromatin remodeling proteins, that has recently been implicated in mediating interactions with monomethylated proteins ([25], see below). A central




Figure 2 VprBP structural motifs and interacting proteins. The 1507 amino acid human VprBP isoform encoded by transcript variant ENST00000563997 in the Ensembl database (release 71) [29] is shown with the domain features for this isoform as described in the database or in the text. VprBP-interacting proteins are identified below the diagram; those for which the binding site has been mapped are shown below the region mediating the association. Proteins targeted for VprBP-dependent ubiquitination are boxed. The region removed after Cre-mediated deletion of a conditional allele [22], and the location of a DNA-PK-dependent phosphorylation site [30] are also indicated.

region, designated by its homology to Lis1 (LisH; residues 846–878), contains a L-X₂-L-X₃₋₅-L-X₃₋₅-L sequence motif that adopts an alpha-helical conformation and is required to mediate oligomerization of VprBP [26]. The carboxyl-terminal half of the protein contains a WD40 domain consisting of four WD40 repeat motifs, which, as discussed above, not only mediate interactions with DDB1, but also support contacts with other substrate and interacting proteins (see below). This region is followed by a stretch of ~100 amino acids rich in acidic residues that may interact with factors that disrupt or subvert the activity of the associated E3 ligase [27,28]. Notably, the acidic region is absent from a shorter murine isoform of VprBP.

To gain insight into the structural and conformational features of VprBP-containing DDB1 and CRL4 complexes, Ahn *et al.* used size-exclusion chromatography coupled to in-line multi-angle light scattering (SEC-MALS) and SDS-PAGE to analyze fully assembled and purified DDB1-VprBP and CRL4^{VprBP} complexes prepared with a form of VprBP lacking the Arm-like domain (VprBP₈₁₇₋₁₅₀₇) [26]. The authors elegantly showed that both complexes contained equimolar amounts of each of the individual proteins, and had an apparent mass that was approximately twice that predicted based on the molecular weight of each subunit, leading them to conclude that both complexes assemble dimeric structures. Further examination of CRL4^{VprBP} complexes by electron microscopy revealed evidence of two-fold rotational symmetry in the structures. A comparison of the

in vitro ubiquitination activity of CRL4^{VprBP(817–1507)} and CRL4^{VprBP(1005–1507)} (which lacks the LisH motif) showed that CRL4^{VprBP(817–1507)} was at least 2-fold more efficient, suggesting that VprBP-mediated dimerization promotes CRL4^{VprBP} ubiquitin transfer activity.

VprBP may also be subjected to post-translational modification. Kim *et al.* reported that DNA-PK phosphorylates VprBP *in vitro* at Ser895, and showed that phospho-Ser895-specific polyclonal antibodies detect phosphorylated VprBP in U2OS cells after etoposide-induced DNA damage [30]. As discussed below, phosphorylation at this site is reported to alleviate VprBP-mediated repression of p53-dependent transcription.

Physiological roles and binding partners of VprBP

VprBP has been implicated in regulating a variety of normal cellular processes, including proliferation, DNA replication, cell cycle progression, telomere maintenance, DNA damage responses, and competition between neighboring cells. The evidence supporting a role for VprBP in these processes, and the context and targets of the associated E3 ligase machinery, where known, are discussed in the following sections.

Proliferation, DNA replication, and cell cycle

Proliferating cells undergo repeated cycles of DNA replication (DNA synthesis or S phase) and cell division (mitosis or M phase), which are temporally separated by gap phases (G1 or G2 phases) (for review, see [31]). Potential replication initiation sites, called replication

origins, are marked, or “licensed”, by the formation of a pre-replication complex (pre-RC) that includes the ORC1-6, CDT1, CDC6, and MCM2-7, beginning late in M phase and proceeding through the G1 phase. During S phase, pre-RCs (30,000-50,000 in mammals) are then activated, or “fired”, following recruitment of DNA replication machinery such as DNA polymerases. DNA replication propagates bidirectionally from the origins until the whole genome is precisely duplicated. Importantly, not all origins are used at the very onset of S phase, but origins are fired in a temporal order by which DNA replication is regulated during S phase [32,33]. Precise DNA replication is of utmost importance to transmit genetic information intact to daughter cells. High fidelity DNA duplication is ensured by S phase checkpoint activation, which inhibits late origin firing in a transient manner to provide time for DNA repair when cells encounter DNA damage during S phase. If damaged DNA is not repaired, cells exit S phase and undergo G2 arrest [34,35].

Recent studies by McCall *et al.* provide several lines of evidence suggesting VprBP is involved in regulating DNA replication [22]. First, silencing VprBP expression was shown to suppress proliferation in U2OS and Rb-inactivated (E7 transduced) WI38 cells and increase the percentage of cells in the S and G2 phases in HeLa cells. Second, VprBP and Cul4A were found to exhibit cell cycle-dependent binding to chromatin in HeLa cells, with the association being primarily restricted to the early S and G2 phases. Third, also in HeLa cells, BrdU labeling studies showed that VprBP silencing markedly reduced DNA replication in middle to late S phase. These cells were not responsive to S-phase inhibitors, indicating that DNA synthesis was completely blocked after VprBP silencing. Fourth, DNA fiber-labeling experiments provided evidence that VprBP silencing in HeLa cells increases the frequency of firing of new replication origins, but does not change the frequency of replication termination or dramatically alter the rate of DNA synthesis. To reconcile the seemingly opposing effects of VprBP silencing on BrdU incorporation during S phase and replication origin firing and DNA synthesis rates, McCall *et al.* suggested that VprBP functions to either stabilize the replication fork or regulates the temporal order of early and late origin firing during S phase [22]. The replication defects observed by BrdU labeling experiments in HeLa cells were further confirmed in primary mouse embryonic fibroblasts (MEFs) in which VprBP expression was conditionally disrupted using a Cre-loxP approach. However, in this case, MEFs lacking VprBP did not accumulate in S phase, but were instead reduced in frequency. This outcome was attributed to an increase in apoptosis observed in VprBP-deficient MEFs as assessed by Annexin V staining. The precise mechanism for how VprBP facilitates DNA replication and S phase

transit in cells remains unclear, as neither the E3 ligase nor the putative substrate(s) that VprBP recruits to it for ubiquitination were established in this study.

Merlin (also called schwannomin) is a tumor suppressor encoded by the *neurofibromatosis type 2* (NF2) gene. Inactivating NF2 mutations have been identified in variety of nervous system tumors including schwannomas, ependymomas, meningiomas and mesotheliomas [36]. To determine the mechanism by which Merlin exerts its anti-proliferative activity, two different groups employed *tandem affinity purification* and *mass spectrometry* (TAP-MS) to identify novel binding partners of Merlin, with both groups identifying DDB1 and VprBP as Merlin-interacting proteins [27,37]. In both studies, pull-down experiments established that Merlin associates with the CRL4^{VprBP} E3 ligase complex, and were used to map Merlin interactions to the far C-terminal acidic region of VprBP (Figure 2). Li *et al.* went further by showing that Merlin specifically co-IP's with the unique components of the CRL4^{VprBP} E3 ligase, but not the alternative EDD-Dyrk2^{DDB1-VprBP} E3 ligase, from nuclear-soluble, but not cytoplasmic/membrane, cell fractions, leading the authors to conclude Merlin translocates to the nucleus to engage CRL4^{VprBP} [27]. Furthermore, this group found that Merlin association with VprBP depended on maintaining Merlin in a “closed” conformation. This closed and active form of Merlin can be converted to an “open”, inactive form by Ser518 phosphorylation, which disrupts an intramolecular interaction between the N- and C-terminal regions of Merlin [38,39].

Using a transient overexpression system, Huang and Chen showed that VprBP downregulates Merlin in a dose-dependent manner by triggering its ubiquitination, and that this effect could be partially overcome by proteasome inhibition [37], leading this group to conclude Merlin is targeted for degradation by CRL4^{VprBP} E3 ligase. However, this conclusion has been challenged by Li *et al.*, who provided evidence that Merlin actually inhibits ubiquitination mediated by the CRL4^{VprBP} E3 ligase [27]. Specifically, levels of VprBP-associated ubiquitination products were shown to diminish as a function of Merlin expression using a Cos7 cell transfection system. Conversely, levels of these products were elevated when Merlin expression was silenced, or the Merlin binding site at the C-terminus of VprBP was removed (VprBP₁₋₁₄₁₇). These authors also showed that silencing Merlin accelerates proliferation in a normal human Schwann cell line or human umbilical vein endothelial cells, but this effect is largely reversed by concomitant VprBP silencing. Finally, genetic evidence for Merlin's function as a CRL4^{VprBP} inhibitor comes from the author's characterization of a panel of tumor-derived mutations, which fell into three categories: those that impair Merlin's ability to translocate into the nucleus,

those that fail to bind VprBP, and those that bind VprBP but do not inhibit CRL4^{VprBP} activity.

Another cell cycle-related protein regulated by VprBP is the microtubule-severing enzyme katanin, which is composed of a regulatory p80 subunit and a catalytic p60 subunit [40]. The association between VprBP and the catalytic subunit of p60 katanin was discovered by Maddika and Chen through a TAP-MS screen for potential substrates of the dual specificity tyrosine-phosphorylation-regulated kinase 2 (Dyrk2), which was of interest for its involvement in various signaling pathways activated during cellular, developmental, and oncogenic processes [41]. This screen identified the HECT E3 ligase EDD (UBR5), DDB1, and VprBP as predominant Dyrk2-associated proteins. Co-IP experiments confirmed these interactions and further excluded Cul4 and Roc1 as binding partners, and also established that Dyrk2 kinase activity is dispensable for binding VprBP. Dyrk2 silencing abolished VprBP association with EDD, but not DDB1, suggesting that Dyrk2 functions as an adaptor bridging EDD to the DDB1-VprBP complex. Moreover, Dyrk2 protein levels were not altered by DDB1, VprBP, or EDD silencing, nor did they fluctuate during cell cycle, suggesting that Dyrk2 did not undergo ubiquitin-dependent degradation mediated by EDD. Alternatively, katanin p60 was considered a potential substrate of the EDD-Dyrk2^{DDB1-VprBP} E3 ligase because its homologue in *Caenorhabditis elegans*, MEI-1, was previously shown to undergo phosphorylation-dependent ubiquitin-mediated degradation by the Dyrk2 homologue MBK2 during meiotic maturation in *C. elegans* [42]. In support of this possibility, Maddika and Chen demonstrated that katanin p60 levels in HeLa cells were increased by silencing of EDD, Dyrk2 or VprBP, and were decreased when these molecules were overexpressed [41]. However, overexpressing a kinase-inactive form of Dyrk2 had no effect on katanin p60 levels, suggesting its degradation depends on Dyrk2-mediated phosphorylation. Consistent with these results, the EDD-Dyrk2^{DDB1-VprBP} complex was shown to support *in vitro* phosphorylation and ubiquitination of katanin p60. Interestingly, silencing of EDD or Dyrk2 in HeLa cells caused G2/M arrest that was alleviated by concomitant silencing of katanin p60. Overexpressing katanin p60 had a similar effect that was overcome by co-expressing wild-type, but not kinase-inactive Dyrk2.

DNA damage responses

Mammalian cells have at least five uracil DNA glycosylases, among which UNG2 plays a critical role in repairing misincorporated or spontaneously generated uracil in genomic DNA [43]. Previously, the HIV protein Vpr was reported to load UNG2 onto VprBP for degradation (see below). More recently, however, Wen *et al.*

found that UNG2 is directly targeted by CRL4^{VprBP} independently of Vpr, but Vpr can enhance VprBP-dependent UNG2 degradation [44]. Thus, silencing DDB1 or VprBP substantially increased UNG2 levels in transiently transfected 293T cells. Interestingly, when overexpressed, UNG2 causes DNA damage [45], colocalizes with the DNA damage marker γ H2AX, and is toxic to cells [46], suggesting UNG2 is a potentially very important substrate of VprBP.

Mcm10 is a DNA replication initiation factor which recruits DNA polymerase α to the pre-RC to initiate DNA replication after CDK2 is activated [47]. UV radiation triggers Mcm10 proteolysis and causes stalling of DNA replication to facilitate DNA repair and avoid erroneous DNA synthesis [48]. Given the known role that CRL1^{Skp2} and CRL4^{Cdt2} E3 ligases play in irradiation-induced DNA damage responses, Kaur *et al.* suspected that one of these two E3 ligases might be responsible for Mcm10 degradation after UV-induced DNA damage [49]. Using a knock-down approach in HeLa cells, the authors excluded the involvement of CRL1^{Skp2}, as well as Cdt2, in UV-induced Mcm10 degradation, but showed that silencing DDB1, Cul4, or Roc1 prevented the loss of Mcm10 after UV treatment. Systematic silencing of known CRL4 substrate recognition subunits identified VprBP as a likely candidate that links Mcm10 to the CRL4 ligase. Pull-down experiments confirmed Mcm10 association with the CRL4^{VprBP} complex, and delimited the interacting region to VprBP₈₆₄₋₁₅₀₇ (Figure 2). The CRL4^{VprBP} E3 ligase was also found to support Mcm10 ubiquitination *in vitro* and *in vivo*.

Hrecka *et al.* provided early evidence suggesting that silencing VprBP expression induced p53 target genes, such as p21, suggesting VprBP directly regulates p53-dependent transcription [50]. To test this possibility, Kim *et al.* analyzed transcription of p53-dependent genes induced after DNA damage, including p21 and Noxa, in MEFs in which VprBP expression was conditionally disrupted [30]. The authors showed that loss of VprBP expression increased p21 and Noxa expression levels induced by etoposide treatment. Using a cell-free assay to evaluate p53-dependent transcription from reconstituted nucleosomal substrates in reactions containing p300 HAT and Acetyl Co-A, the authors next showed that intact, but not denatured, VprBP suppressed p53-dependent transcription on nucleosomal, but not histone-free, DNA templates, as long as VprBP was added before p300, suggesting VprBP may block p300-dependent acetylation. This outcome was traced to VprBP's ability to bind to unmodified histone H3 tails and was minimally mediated by VprBP₍₇₅₁₋₁₅₀₇₎, which encompasses the LisH and WD40 domains as well as the acidic C-terminus (Figure 2). Consistent with this finding, ChIP experiments demonstrated that knock-

down of histone deacetylase (HDAC1) or VprBP, or etoposide treatment led to increased histone H3 acetylation and p53 occupancy at p53-dependent promoters; conversely, treatment with etoposide led to loss of HDAC1 and VprBP occupancy of the same promoters. These data suggested that VprBP physically associates with HDAC1 and p53. Evidence supporting this possibility was obtained using co-IP experiments, but the interacting regions in VprBP were not mapped. Because VprBP levels remained constant after DNA damage, the authors speculated that VprBP is subjected to post-translational modification after DNA damage to release VprBP bound to unmodified histone H3 tails. By screening a panel of kinases, acetyltransferases, and methyltransferases implicated in DNA damage responses, the authors identified DNA-PK as able to post-translationally modify VprBP. The phosphorylation site was mapped to Ser895, and an alanine substitution at this residue was demonstrated to attenuate p53-dependent transcription, and impair histone acetylation and release of VprBP from p53-dependent promoters in response to DNA damage. These data, taken together, led the authors to propose a model in which VprBP, in cooperation with HDAC1, removes and blocks acetylation of histone H3 tails to repress p53-dependent transcription. In response to DNA damage, DNA-PK phosphorylates VprBP at Ser895, which releases VprBP binding to histone H3, thereby allowing p53-dependent promoter activation.

The products of the recombination activating genes 1 and 2 (RAG1/2) are required to initiate V(D)J recombination, a form of site-specific DNA rearrangement that is responsible for assembling the immunoglobulin (Ig) and T cell receptor genes in B and T lymphocytes, respectively [51]. The N-terminal region of RAG1 (residues 1–383 of 1040), though not absolutely required for V(D)J recombination activity, is evolutionarily conserved and is necessary for efficient and high-fidelity rearrangement of the endogenous antigen receptor loci. The N-terminal region of RAG1 contains a RING domain that functions *in vitro* as an E3 ligase, but the *in vivo* functionality and physiological targets of RAG1 E3 ligase activity, if any, remains unclear. Moreover, since many RING-type E3 ligases form multi-subunit assemblies [52], RAG1 could plausibly associate with other accessory proteins to support its putative function as an E3 ligase. In support of this possibility, Kassmeier *et al.* showed that under mild purification conditions, novel proteins co-purified with full-length RAG1, one of which was identified as VprBP using mass spectrometry [53]. Subsequent experiments provided evidence that DDB1, Cul4A, and Roc1, but not EDD and Dyrk2, co-purify full-length RAG1, and that RAG1 association with the CRL4^{VprBP} complex is mediated primarily by RAG1 interactions with the WD40 domain of VprBP (Figure 2). This co-purified complex

supported E3 ligase activity *in vitro*: this activity was not directed at the RAG proteins themselves, and was not obviously impaired by cysteine mutations in the RING domain of RAG1, leading the authors to speculate that RAG1 serves as a scaffold to recruit the CRL4^{VprBP} to ubiquitinate one or more as-yet unidentified substrates. Evidence for the physiological significance of VprBP function in lymphocytes was obtained by conditionally disrupting VprBP expression in the B cell lineage. These animals showed an arrest in B cell development at the pro-B-to-pre-B cell transition, which was associated with an increase in S phase and apoptotic cells. Evidence for abnormal repair of V(D)J recombination intermediates was also detected. Recently, we have found that B cell development can be partially rescued by enforced expression of Bcl2, but most mature B cells emerging in this case express the lambda light chain, rather than the more commonly expressed kappa light chain (Palmer and Swanson, unpublished data). This observation suggests that VprBP is not absolutely required for V(D)J recombination, although its involvement in the DNA repair phase of this process cannot yet be excluded. An intriguing alternative possibility is that VprBP regulates the accessibility or positioning of the kappa locus to permit RAG-mediated DNA rearrangements over the ~3 Mb span of the kappa locus. Because the lambda locus is only about 1/10th the size of the kappa locus and contains many fewer gene segments, it may not require significant architectural changes to support V(D)J recombination, and therefore may undergo RAG-mediated rearrangement in a largely VprBP-independent manner.

Telomerase regulation

Telomerase is an enzyme responsible for adding DNA sequence repeats to chromosomal ends after DNA replication, which is necessary to maintain genomic stability and prevent gradual loss of genetic information with each cell division. The telomerase holoenzyme contains the telomerase reverse transcriptase (TERT) subunit, telomerase RNA (TERC), and several accessory protein subunits [54]. Based on the observation that telomerase activity is not well correlated with TERT transcript levels among different cell types, and that TERT protein exhibits a short half-life in HeLa cells, Jung *et al.* speculated that TERT is regulated at the post-translational level by phosphorylation and/or ubiquitin-dependent degradation [55]. These authors identified Dyrk2 as a candidate TERT regulatory kinase by systematically over-expressing a panel of protein kinases and evaluating their ability to down-regulate TERT protein in HeLa cells. The authors subsequently showed that Dyrk2 interacts with and phosphorylates TERT at Ser457, and promotes its *in vitro* ubiquitination. Notably, however, kinase-inactive Dyrk2 binds but does not phosphorylate

TERT, and does not trigger its degradation in cells. Consistent with these findings, depletion of Dyrk2 was shown to upregulate TERT expression and increased the half-life of the protein. Interestingly, although knock-down of Dyrk2 disrupted TERT association with VprBP and EDD, it had little effect on TERT-DDB1 interactions. This result is puzzling and remains unexplained. However, it raises the possibility that DDB1, rather than VprBP, is responsible for bringing TERT into proximity to EDD. In this regard, it is noteworthy that the region of VprBP interacting with TERT was not mapped, and the Dyrk2 and TERT truncation mutants used to map Dyrk2-TERT interactions were not evaluated for the presence of co-purifying DDB1 or VprBP, which could conceivably bridge Dyrk2 and TERT in the assay. Finally, the authors showed that TERT-Dyrk2 protein interactions were primarily limited to the G2/M phase, and were correlated with a decrease in TERT protein levels. In contrast, TERT-Dyrk2 association was not apparent during S phase, when telomerase activity is expected to be highest. Taken together, these data led the authors to suggest a model in which the TERT protein synthesizes a telomere repeat sequence at the early S phase of the cell cycle, and as the cell transitions to the G2/M phase, the EDD-Dyrk2 E3 ligase targets TERT protein for degradation to suppress telomerase activity.

Turnover of methylated proteins

Enhancer of zeste homolog 2 (EZH2) is a methyltransferase that specifically mediates histone H3K27 methylation and has been found to be deregulated in a variety of cancer types [56]. Given its likely role in tumorigenesis, Lee *et al.* were interested in identifying potential non-histone targets of EZH2 activity [25]. A computational screen of proteins carrying the amino acid sequence R-K-S in histone H3 that is targeted by EZH2 identified the orphan nuclear receptor ROR α as carrying a potential acceptor site for methylation by EZH2. Subsequent studies demonstrated that EZH2 catalyzes monomethylation of ROR α at K38 *in vitro*, and that loss of EZH2 activity or a K38A ROR α mutation increased cellular ROR α protein levels and extended its half-life, but did not alter ROR α transcript levels, suggesting ROR α methylation triggered its degradation. This hypothesis was further supported by the observation that wild-type, but not K38A, ROR α protein ubiquitination products were increased in cells treated with the proteasome inhibitor MG132. To determine the putative ubiquitin ligase responsible for mediating ROR α degradation, FLAG-ROR α was purified from stably transfected HEK293 cells treated with MG132, and ROR α -associating proteins were identified by mass spectrometry, yielding VprBP and DDB1 as ROR α -interacting proteins. Subsequent studies established

that Cul4 associated with ROR α in a VprBP, DDB1, and EZH2-dependent manner, and showed that the VprBP-ROR α interaction required active EZH2, suggesting the interaction was methylation dependent. The VprBP interacting region was mapped to a putative chromo-like domain in the N-terminal region (residues 562–593, Figure 2). The authors established the functional significance of ROR α methylation-induced, ubiquitin-dependent degradation, by showing that transcription from ROR α -dependent promoters and target genes was enhanced by a K38A ROR α mutation or by silencing VprBP or EZH2 expression. Consistent with data suggesting EZH2 regulates ROR α levels, the authors showed that breast cancer cells and tumors which overexpress EZH2 have lower ROR α levels compared to normal controls. In addition, tumor cell growth in soft agar could be suppressed in the breast cancer cell line MCF7 by ectopically expressing ROR α , inhibiting EZH2 activity, or silencing VprBP.

Neighboring cell competition

In the *Drosophila* model system, faster growing cells were discovered to induce apoptosis of surrounding slower growing cells in mixed cell culture by a process called “cell competition”. This process was found to depend on a tumor suppressor gene called *Lethal giant larvae* (Lgl) [57]. Using the mammalian Lgl homologue (mLgl2) as bait to search for factors that mediate Lgl-dependent cell competition, Tamori *et al.* identified VprBP as a Lgl-binding protein by mass spectrometry and showed that a C-terminal VprBP fragment containing the WD40 domains and the acidic region is minimally required to associate with mLgl2 [58] (Figure 2). In *Drosophila*, disruption of the VprBP homolog (called Mahjong) caused growth retardation and lethality at the late pupal stage. In both *Drosophila* and mammalian cells, loss of Mahjong/VprBP expression rendered cells susceptible to apoptosis initiated by neighboring wild-type cells, possibly through the activation of the JNK pathway. In this study, the authors did not report whether components of the CRL4 or EDD-Dyrk2 E3 ubiquitin ligases associate with the VprBP-mLgl2 complex, nor whether Lgl (or mLgl2) undergoes VprBP-dependent ubiquitination. Thus, the mechanism by which VprBP regulates Lgl to influence cell competition remains unclear.

VprBP as a target of viral proteins

VprBP is targeted by the Vpr and Vpx accessory factors of primate lentiviruses, where they are thought to hijack the function of the CRL4^{VprBP} E3 ligase. The background and significance of these discoveries have been recently reviewed [2], and so will not be covered in depth here. What is notable for this review is that

engagement of CRL4^{VprBP} by Vpr (but not Vpx) causes cell cycle arrest at the G2 phase. By contrast, Vpx association with the CRL4^{VprBP} E3 ligase is required to overcome host restriction and enable viral infectivity of myeloid cells. Vpr and Vpx appear to facilitate recruitment of different substrates to the CRL4^{VprBP} ligase: Vpr promotes loading of the uracil DNA glycosylases UNG2 and SMUG1 (single-strand-selective monofunctional uracil-DNA glycosylase 1) [44,59,60], whereas Vpx recruits SAMHD1 (sterile alpha motif and HD domain-containing protein-1), a deoxyribonucleoside triphosphate (dNTP) triphosphohydrolase thought to inhibit HIV/SIV infection by maintaining cellular dNTP levels below the threshold required for robust viral reverse transcriptase activity [61-66]. As discussed above, Vpr may enhance the normal turnover of UNG2 by CRL4^{VprBP}, whereas Vpx is thought to recruit SAMHD1 as a novel target of CRL4^{VprBP} to inhibit SAMHD1 enzymatic activity [67] and promote its degradation [61]. Notably, the Vpr-mediated G2 arrest phenotype does not depend on Vpr binding to UNG2 [68].

Interestingly, Wang *et al.* recently reported that Vpr also enhances TERT degradation mediated by VprBP [69], which may provide a mechanism to explain the downregulation of telomerase activity following HIV-1 infection [70,71]. These authors showed that knock-down of VprBP, but not Cul4A, alleviated Vpr-induced TERT degradation; a Vpr Q65R mutation that abolishes binding to VprBP also prevented Vpr-induced TERT degradation. The involvement of EDD-Dyrk2 E3 ligase was implied by the finding that EDD and DDB1 associate with Vpr in co-IP experiments, but their requirement for Vpr-induced TERT degradation was not formally established. While Dyrk2 was found to promote TERT ubiquitylation *in vitro*, its presence in Vpr immunoprecipitates and its requirement for Vpr-mediated TERT degradation in cells was not tested.

Based on an alignment of multiple VprBP sequences obtained from a yeast two-hybrid screen for Vpr-interacting proteins, Le Rouzic *et al.* concluded that Vpr interacts with the WD40 domain of VprBP [72]. This finding contrasts somewhat with data published by Zhang *et al.* showing that a VprBP fragment encompassing residues 636-1507, but not 1100-1507 (which contains most of the WD40 domain), co-IP's Vpr from insect cells expressing both proteins [11].

Another viral protein that targets VprBP is human cytomegalovirus (HCMV) UL35 protein [28]. Like Merlin, UL35 binds to the far C-terminal acidic region of VprBP (Figure 2), and, like Vpr [73,74], UL35 overexpression triggers G2 arrest associated with cdc2 phosphorylation [28]. Silencing VprBP expression was shown to block UL35-mediated cdc2 phosphorylation, but its effect on cell cycle was not reported [28]. Although DDB1 was

found to co-IP with UL35, interactions with other components of the CRL4 or EDD-Dyrk2 E3 ligases were not formally established. Thus, whether UL35 functions to inhibit or hijack one or the other E3 ligase currently remains unclear.

Remaining questions

A number of very interesting questions regarding the normal function of VprBP and its targeting by viral accessory proteins remain to be answered. One important question centers on whether VprBP levels are limiting in the cell in comparison to the CRL4 and EDD-Dyrk2 E3 ligases, and if so, what conditions are necessary to enable VprBP to service these two E3 ligases if both are expressed in the same cell. Since VprBP is a demonstrated substrate of DNA-PK [30], one might imagine that phosphorylation, or an alternative post-translational modification, could provide a mechanism to influence which E3 ligase VprBP associates with at a given time within the cell. Of course, similar mechanisms may act on the core E3 ligase components themselves to prevent VprBP association, but this would presumably affect interactions with other substrate recognition subunits as well, and may therefore be less likely to occur. The dual specificity of VprBP for both the CRL4 and EDD-Dyrk2 E3 ligases also raises some concerns about whether effects observed in VprBP knock-down experiments can be uniquely attributed to inhibiting one or the other E3 ligase, particularly in situations where the CRL4 and EDD/UBR E3 ligases may have overlapping regulatory roles, such as during DNA damage responses [75-77].

Another central unanswered question pertains to the molecular mechanism by which Merlin binding to VprBP inhibits CRL4^{VprBP} activity. Among possible scenarios that could be imagined include competitive inhibition of substrate binding or blocking of conformational changes that facilitate ubiquitin transfer. In this respect, it is intriguing that Merlin binds to the same site on VprBP as UL35, but for reasons that remain unclear, does not trigger G2 arrest like UL35 [28]. The observation that Vpr also induces G2 arrest, but binds VprBP in a different location than UL35 (Figure 2), raises the possibility that Vpr and UL35 share a common mechanism for inducing G2 arrest that results from inhibiting, rather than redirecting, E3 ligase activity.

A third major question is the relationship between VprBP oligomerization and VprBP function and its implication for experimental interpretation. For example, Kim *et al.* reported that VprBP-mediated histone H3 binding and suppression of p53 target gene transcription was supported by VprBP₇₅₁₋₁₅₀₇, which contains the LisH and WD40 domains, but not by VprBP₉₁₀₋₁₅₀₇, which lacks the LisH region, leading the authors to

conclude that the LisH region is responsible for histone H3 binding [30]. However, since the LisH region has been shown to mediate VprBP oligomerization [26], an alternative interpretation is that enhanced activity of VprBP₇₅₁₋₁₅₀₇ relative to VprBP₉₁₀₋₁₅₀₇ is attributed to the ability of VprBP₇₅₁₋₁₅₀₇ to oligomerize when binding histone H3 on nucleosomal DNA substrates, which could enhance otherwise weak intrinsic protein-protein interactions by avidity.

Given that DDB1 as well as several putative substrate and other interacting proteins associate with VprBP through the WD40 domain (Figure 2), another key question is the following: how can the WD40 domain accommodate both DDB1 and one or more of these other interacting proteins in the same macromolecular complex? One explanation may be that DDB1 interacts with only a portion of the WD40 domain in VprBP (which permits other proteins to access this region), and may also rely on contacts outside of the WD40 domain to maintain stable association with VprBP. In support of these possibilities, Kassmeier *et al.* showed that a VprBP₁₋₁₀₀₀ fragment lacking the WD40 domain associates with DDB1 [53], and residual DDB1 binding was detected with a VprBP₁₋₇₅₀ fragment by others [22]. Structural studies in several laboratories suggest many DCAFs interact with DDB1 through two different interfaces: one mediated by part of the WD40 domain which makes hydrophobic contacts with the BPA domain of DDB1, and the other mediated by an amino-terminal alpha-helical motif that is inserted into a cleft between the BPA and BPC domains [18-21]. Although a comparable alpha-helical motif was not identified in VprBP using multiple sequence alignment approaches [18,21], the sequence motif is quite short (13–20 residues) and not highly conserved, so its presence may yet remain unrecognized somewhere within the first 750–1000 residues of VprBP. Furthermore, the WD40 domain in DDB1-associated substrate recognition subunits may contact other ligands using the face opposite the one used to bind DDB1. For example, DDB2 uses one side of its WD40 beta-propeller to contact DDB1 and the other side to bind substrate DNA [18,20]. The WD40 domain in VprBP may similarly be used to associate with both DDB1 and substrate molecules.

Another interesting question is whether VprBP functions solely to promote polyubiquitination and degradation of targeted substrates. For example, Mcm10 was shown to undergo VprBP-dependent polyubiquitination and degradation in response to DNA damage [49]. However, VprBP silencing alone does not affect Mcm10 protein levels, suggesting VprBP does not normally control Mcm10 turnover. Interestingly, Mcm10 is mono- to di-ubiquitinated during the G1-to-S phase transition, which promotes its function during DNA replication in budding

yeast [78], and Mcm10 silencing causes cell cycle arrest at the G2 phase by checkpoint activation in mammalian cells [79]. These data raise the possibility that VprBP positively regulates Mcm10 function by mediating mono to di-ubiquitination in mammalian cells.

In summary, VprBP has been implicated in regulating a wide variety of normal cellular processes and is targeted by host and viral accessory proteins to inhibit or subvert its affiliated E3 ligases. At present, our understanding of whether or how VprBP can switch its allegiance between the CRL4 and EDD-Dyrk2 E3 ligases, especially in pathways where both E3 ligases may play a regulatory role, remains limited. Clarifying the existence and nature of this interplay will greatly improve our understanding of how VprBP regulates cellular processes through the CRL4 and EDD-Dyrk2 E3 ligases, and allow us to recognize the full implications of their inhibition or hijacking by host and pathogen-associated factors.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TN, KM, and PCS all contributed in drafting and editing the manuscript, and all authors read and approved the final manuscript.

Acknowledgments

PCS gratefully acknowledges funding from the National Institutes of Health (5R01 GM102487). TN thanks Yue Xiong (University of North Carolina at Chapel Hill) for continuous encouragement and support.

Received: 3 June 2013 Accepted: 3 September 2013

Published: 13 September 2013

References

1. Komander D, Rape M: **The ubiquitin code.** *Annu Rev Biochem* 2012, **81**:203–229.
2. Romani B, Cohen EA: **Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase.** *Curr Opin Virol* 2012, **2**(6):755–763.
3. Viswanathan K, Fruh K, DeFilippis V: **Viral hijacking of the host ubiquitin system to evade interferon responses.** *Curr Opin Microbiol* 2010, **13**(4):517–523.
4. Hicks SW, Galan JE: **Hijacking the host ubiquitin pathway: structural strategies of bacterial E3 ubiquitin ligases.** *Curr Opin Microbiol* 2010, **13**(1):41–46.
5. Metzger MB, Hristova VA, Weissman AM: **HECT and RING finger families of E3 ubiquitin ligases at a glance.** *J Cell Sci* 2012, **125**(Pt 3):531–537.
6. Sarikas A, Hartmann T, Pan ZQ: **The cullin protein family.** *Genome Biol* 2011, **12**(4):220.
7. Duda DM, Scott DC, Calabrese MF, Zimmerman ES, Zheng N, Schulman BA: **Structural regulation of cullin-RING ubiquitin ligase complexes.** *Curr Opin Struct Biol* 2011, **21**(2):257–264.
8. Scheffner M, Kumar S: **Mammalian HECT ubiquitin-protein ligases: Biological and pathophysiological aspects.** *Biochim Biophys Acta* 2013. Epub ahead of print.
9. Shearwin-Whyatt L, Dalton HE, Foot N, Kumar S: **Regulation of functional diversity within the Nedd4 family by accessory and adaptor proteins.** *Bioessays* 2006, **28**(6):617–628.
10. Zhao LJ, Mukherjee S, Narayan O: **Biochemical mechanism of HIV-1 Vpr function. Specific interaction with a cellular protein.** *J Biol Chem* 1994, **269**(22):15577–15582.
11. Zhang S, Feng Y, Narayan O, Zhao LJ: **Cytoplasmic retention of HIV-1 regulatory protein Vpr by protein-protein interaction with a novel human cytoplasmic protein VprBP.** *Gene* 2001, **263**(1–2):131–140.

12. Jin J, Arias EE, Chen J, Harper JW, Walter JC: **A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1.** *Mol Cell* 2006, **23**(5):709–721.
13. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N: **Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery.** *Nature* 2006, **443**(7111):590–593.
14. He YJ, McCall CM, Hu J, Zeng Y, Xiong Y: **DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases.** *Genes Dev* 2006, **20**(21):2949–2954.
15. Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H: **CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation.** *Nat Cell Biol* 2006, **8**(11):1277–1283.
16. Higa LA, Zhang H: **Stealing the spotlight: CUL4-DDB1 ubiquitin ligase docks WD40-repeat proteins to destroy.** *Cell Div* 2007, **2**:5.
17. Lee J, Zhou P: **DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase.** *Mol Cell* 2007, **26**(6):775–780.
18. Fischer ES, Scrima A, Bohm K, Matsumoto S, Lingaraju GM, Faty M, Yasuda T, Cavadini S, Wakasugi M, Hanaoka F, et al: **The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation.** *Cell* 2011, **147**(5):1024–1039.
19. Yeh JI, Levine AS, Du S, Chinte U, Ghodke H, Wang H, Shi H, Hsieh CL, Conway JF, Van Houten B, et al: **Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB) dimerization and its roles in chromatinized DNA repair.** *Proc Natl Acad Sci USA* 2012, **109**(41):E2737–E2746.
20. Scrima A, Konickova R, Czyzewski BK, Kawasaki Y, Jeffrey PD, Groisman R, Nakatani Y, Iwai S, Pavletich NP, Thoma NH: **Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex.** *Cell* 2008, **135**(7):1213–1223.
21. Li T, Robert El, van Breugel PC, Strubin M, Zheng N: **A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery.** *Nat Struct Mol Biol* 2010, **17**(1):105–111.
22. McCall CM, de Marval PL M, Chastain PD, Jackson SC 2nd, He YJ, Kotake Y, Cook JG, Xiong Y: **Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development.** *Mol Cell Biol* 2008, **28**(18):5621–5633.
23. Peifer M, Berg S, Reynolds AB: **A repeating amino acid motif shared by proteins with diverse cellular roles.** *Cell* 1994, **76**(5):789–791.
24. Huber AH, Nelson WJ, Weis WI: **Three-dimensional structure of the armadillo repeat region of beta-catenin.** *Cell* 1997, **90**(5):871–882.
25. Lee JM, Lee JS, Kim H, Kim K, Park H, Kim JY, Lee SH, Kim IS, Kim J, Lee M, et al: **EZH2 generates a methyl degran that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.** *Mol Cell* 2012, **48**(4):572–586.
26. Ahn J, Novince Z, Concel J, Byeon CH, Makhov AM, Byeon IJ, Zhang P, Gronenborn AM: **The Cullin-RING E3 Ubiquitin Ligase CRL4-DCAF1 Complex Dimerizes via a Short Helical Region in DCAF1.** *Biochemistry* 2011, **50**(8):1359–1367.
27. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, et al: **Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.** *Cell* 2010, **140**(4):477–490.
28. Salsman J, Jagannathan M, Paladino P, Chan PK, Dellaire G, Raught B, Frappier L: **Proteomic profiling of the human cytomegalovirus UL35 gene products reveals a role for UL35 in the DNA repair response.** *J Virol* 2012, **86**(2):806–820.
29. Flicek P, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, Fitzgerald S, et al: **Ensembl 2012.** *Nucleic Acids Res* 2012, **40**(Database issue):D84–D90.
30. Kim K, Heo K, Choi J, Jackson S, Kim H, Xiong Y, An W: **Vpr-binding protein antagonizes p53-mediated transcription via direct interaction with H3 tail.** *Mol Cell Biol* 2012, **32**(4):783–796.
31. Sclafani RA, Holzen TM: **Cell cycle regulation of DNA replication.** *Annu Rev Genet* 2007, **41**:237–280.
32. Symeonidou IE, Taraviras S, Lygerou Z: **Control over DNA replication in time and space.** *FEBS Lett* 2012, **586**(18):2803–2812.
33. Mechali M: **Eukaryotic DNA replication origins: many choices for appropriate answers.** *Nat Rev Mol Cell Biol* 2010, **11**(10):728–738.
34. Bartek J, Lukas C, Lukas J: **Checking on DNA damage in S phase.** *Nat Rev Mol Cell Biol* 2004, **5**(10):792–804.
35. Ciccia A, Elledge SJ: **The DNA damage response: making it safe to play with knives.** *Mol Cell* 2010, **40**(2):179–204.
36. Ammoun S, Hanemann CO: **Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.** *Nat Rev Neurol* 2011, **7**(7):392–399.
37. Huang J, Chen J: **VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation.** *Oncogene* 2008, **27**(29):4056–4064.
38. Kissil JL, Johnson KC, Eckman MS, Jacks T: **Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization.** *J Biol Chem* 2002, **277**(12):10394–10399.
39. Xiao GH, Beeser A, Chernoff J, Testa JR: **p21-activated kinase links Rac/Cdc42 signaling to merlin.** *J Biol Chem* 2002, **277**(2):883–886.
40. Roll-Mecak A, McNally FJ: **Microtubule-severing enzymes.** *Curr Opin Cell Biol* 2010, **22**(1):96–103.
41. Maddika S, Chen J: **Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase.** *Nat Cell Biol* 2009, **11**(4):409–419.
42. Lu C, Mains PE: **The C. elegans anaphase promoting complex and MBK-2/DYRK kinase act redundantly with CUL-3/MEL-26 ubiquitin ligase to degrade MEI-1 microtubule-severing activity after meiosis.** *Dev Biol* 2007, **302**(2):438–447.
43. Visnes T, Doseth B, Pettersen HS, Hagen L, Sousa MM, Akbari M, Otterlei M, Kavli B, Slupphaug G, Krokan HE: **Uracil in DNA and its processing by different DNA glycosylases.** *Philos Trans R Soc Lond B Biol Sci* 2009, **364**(1517):563–568.
44. Wen X, Casey Klockow L, Nekorchuk M, Sharifi HJ, de Noronha CM: **The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover.** *PLoS One* 2012, **7**(1):e30939.
45. Elder RT, Zhu X, Priet S, Chen M, Yu M, Navarro JM, Sire J, Zhao Y: **A fission yeast homologue of the human uracil-DNA-glycosylase and their roles in causing DNA damage after overexpression.** *Biochem Biophys Res Commun* 2003, **306**(3):693–700.
46. Zeitlin SG, Chapados BR, Baker NM, Tai C, Slupphaug G, Wang JY: **Uracil DNA N-glycosylase promotes assembly of human centromere protein A.** *PLoS One* 2011, **6**(3):e17151.
47. Zhu W, Ukomadu C, Jha S, Senga T, Dhar SK, Wohlschlegel JA, Nutt LK, Kornbluth S, Dutta A: **Mcm10 and And-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication.** *Genes Dev* 2007, **21**(18):2288–2299.
48. Sharma A, Kaur M, Kar A, Ranade SM, Saxena S: **Ultraviolet radiation stress triggers the down-regulation of essential replication factor Mcm10.** *J Biol Chem* 2010, **285**(11):8352–8362.
49. Kaur M, Khan MM, Kar A, Sharma A, Saxena S: **CRL4-DDB1-VPRBP ubiquitin ligase mediates the stress triggered proteolysis of Mcm10.** *Nucleic Acids Res* 2012, **40**(15):7332–7346.
50. Hrecka K, Gierszewska M, Srivastava S, Kozaczekiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J: **Lentiviral Vpr usurps Cul4-DDB1 [VprBP] E3 ubiquitin ligase to modulate cell cycle.** *Proc Natl Acad Sci USA* 2007, **104**(28):11778–11783.
51. Schatz DG, Swanson PC: **V(D)J Recombination: Mechanisms of Initiation.** *Annu Rev Genet* 2011, **14**:167–202.
52. Deshaies RJ, Joazeiro CA: **RING domain E3 ubiquitin ligases.** *Annu Rev Biochem* 2009, **78**:399–434.
53. Kassmeier MD, Mondal K, Palmer VL, Raval P, Kumar S, Perry GA, Anderson DK, Ciborowski P, Jackson S, Xiong Y, et al: **VprBP binds full-length RAG1 and is required for B-cell development and V(D) J recombination fidelity.** *EMBO J* 2011, **31**(4):945–958.
54. Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD, Alonso DF: **Telomere structure and telomerase in health and disease (review).** *Int J Oncol* 2012, **41**(5):1561–1569.
55. Jung HY, Wang X, Jun S, Park JI: **Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation.** *J Biol Chem* 2013, **288**(10):7252–7262.
56. Chang CJ, Hung MC: **The role of EZH2 in tumour progression.** *Br J Cancer* 2012, **106**(2):243–247.
57. Grzeschik NA, Amin N, Secombe J, Brumby AM, Richardson HE: **Abnormalities in cell proliferation and apico-basal cell polarity are separable in Drosophila lgl mutant clones in the developing eye.** *Dev Biol* 2007, **311**(1):106–123.
58. Tamori Y, Bialucha CU, Tian AG, Kajita M, Huang YC, Norman M, Harrison N, Poulton J, Ivanovitch K, Disch L, et al: **Involvement of Lgl and Mahjong/VprBP in cell competition.** *PLoS Biol* 2010, **8**(7):e1000422.

59. Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, Gronenborn AM: HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. *J Biol Chem* 2010, **285**(48):37333–37341.
60. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR: Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. *Journal of virology* 2005, **79**(17):10978–10987.
61. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J: Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. *Nature* 2011, **474**(7353):658–661.
62. Ahn J, Hao C, Yan J, DeLucia M, Mehrens J, Wang C, Gronenborn AM, Skowronski J: HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. *J Biol Chem* 2012, **287**(15):12550–12558.
63. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M: SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature* 2011, **474**(7353):654–657.
64. Berger A, Sommer AFR, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, et al: SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. *PLoS pathogens* 2011, **7**(12):e1002425.
65. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HCT, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, et al: HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. *Nature* 2011, **480**(7377):379–382.
66. Powell RD, Holland PJ, Hollis T, Perrino FW: Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. *The J Biol Chem* 2011, **286**(51):43596–43600.
67. Delucia M, Mehrens J, Wu Y, Ahn J: HIV-2 and SIVmac accessory virulence factor Vpx down-regulates SAMHD1 catalysis prior to proteasome-dependent degradation. *J Biol Chem* 2013, **288**(26):19116–19126.
68. Selig L, Benichou S, Rogel ME, Wu LI, Vodicka MA, Sire J, Benarous R, Emerman M: Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. *J Virol* 1997, **71**(6):4842–4846.
69. Wang X, Singh S, Jung H-Y, Yang G, Jun S, Sastry KJ, Park J-H: HIV-1 Vpr Protein Inhibits Telomerase Activity via the EDD-DDB1-VPRBP E3 Ligase Complex. *The J Biol Chem* 2013, **288**(22):15474–15480.
70. Ballon G, Ometto L, Righetti E, Cattelan AM, Masiero S, Zanchetta M, Chieco-Bianchi L, De Rossi A: Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. *J Infect Dis* 2001, **183**(3):417–424.
71. Franzese O, Adamo R, Pollicita M, Comandini A, Laudisi A, Perno CF, Aquaro S, Bonmassar E: Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4(+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). *J Med Virol* 2007, **79**(5):639–646.
72. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F: HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. *Cell Cycle* 2007, **6**(2):182–188.
73. Re F, Braaten D, Franke EK, Luban J: Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. *J Virol* 1995, **69**(11):6859–6864.
74. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol* 1995, **69**(11):6705–6711.
75. Munoz MA, Saunders DN, Henderson MJ, Clancy JL, Russell AJ, Lehrbach G, Musgrove EA, Watts CK, Sutherland RL: The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. *Cell Cycle* 2007, **6**(24):3070–3077.
76. Li JM, Jin J: CRL Ubiquitin Ligases and DNA Damage Response. *Front Oncol* 2012, **2**:29.
77. Ling S, Lin WC: EDD inhibits ATM-mediated phosphorylation of p53. *J Biol Chem* 2011, **286**(17):14972–14982.
78. Das-Bradoo S, Ricke RM, Bielinsky AK: Interaction between PCNA and diubiquitinated Mcm10 is essential for cell growth in budding yeast. *Mol Cell Biol* 2006, **26**(13):4806–4817.
79. Park JH, Bang SW, Kim SH, Hwang DS: Knockdown of human MCM10 activates G2 checkpoint pathway. *Biochem Biophys Res Commun* 2008, **365**(3):490–495.

doi:10.1186/1471-2199-14-22

Cite this article as: Nakagawa et al.: VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD/UBR5 E3 ubiquitin ligases. *BMC Molecular Biology* 2013 **14**:22.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

